Adial Pharmaceuticals, Inc.ADILNASDAQ
Loading
Operating Income Growth Under PressureDecelerating
Percentile Rank63
3Y CAGR-33.3%
Year-over-Year Change
Year-over-year operating income growth rate
3Y CAGR
-33.3%/yr
vs +67.0%/yr prior
Acceleration
-100.3pp
Decelerating
Percentile
P63
Within normal range
vs 3Y Ago
0.3x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | 6.30% |
| Q2 2025 | 16.96% |
| Q1 2025 | -16.83% |
| Q4 2024 | 12.24% |
| Q3 2024 | 3.31% |
| Q2 2024 | -23.97% |
| Q1 2024 | -3.43% |
| Q4 2023 | -31.36% |
| Q3 2023 | 8.09% |
| Q2 2023 | 34.88% |
| Q1 2023 | 12.66% |
| Q4 2022 | -1.68% |
| Q3 2022 | 21.25% |
| Q2 2022 | -6.04% |
| Q1 2022 | 48.86% |
| Q4 2021 | -47.19% |
| Q3 2021 | 7.73% |
| Q2 2021 | 9.02% |
| Q1 2021 | -39.47% |
| Q4 2020 | -3.96% |
| Q3 2020 | -83.55% |
| Q2 2020 | 20.93% |
| Q1 2020 | -10.01% |
| Q4 2019 | -19.77% |
| Q3 2019 | 19.14% |
| Q2 2019 | 4.01% |
| Q1 2019 | -106.33% |
| Q4 2018 | 71.43% |
| Q3 2018 | -119.13% |
| Q2 2018 | -412.93% |
| Q1 2018 | -5.51% |
| Q4 2017 | -22.63% |
| Q3 2017 | -8.67% |
| Q2 2017 | -42.39% |
| Q1 2017 | -93.53% |
| Q4 2016 | 13.89% |
| Q3 2016 | -6.35% |
| Q2 2016 | 23.88% |
| Q1 2016 | 0.00% |